Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.63 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18603295 | 1.00 | GRM2 (0.63) | GRM2SIRT2SIRT1MMP1MMP13 | |
| SCHEMBL18603269 | 0.84 | GRM2 (0.57) | GRM2SIRT2SIRT1MMP1MMP13 | |
| SCHEMBL18622408 | 0.84 | GRM2 (0.57) | GRM2SIRT2SIRT1MMP1MMP13 | |
| SCHEMBL28915848 | 0.84 | GRM2 (0.57) | GRM2SIRT2SIRT1MMP1MMP13 | |
| SCHEMBL18603263 | 0.84 | GRM2 (0.56) | GRM2SIRT2SIRT1MMP1MMP13 | |
| SCHEMBL18603262 | 0.84 | GRM2 (0.56) | GRM2SIRT2SIRT1MMP1MMP13 | |
| SCHEMBL27476723 | 0.83 | SIRT1 (0.56) | GRM2SIRT2SIRT1KMT2APOLB | |
| SCHEMBL1448065 | 0.83 | SIRT1 (0.56) | GRM2SIRT2SIRT1KMT2APOLB | |
| SCHEMBL18603268 | 0.83 | GRM2 (0.56) | GRM2SIRT2SIRT1MMP1MMP13 | |
| SCHEMBL31564563 | 0.82 | SIRT2 (0.52) | GRM2SIRT2SIRT1MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026080-B | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments | 勃林格殷格翰国际有限公司 | 2021-06-11 | — | — | CN | disclosed |
| EP-3347353-B1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-12-18 | — | — | US | disclosed |
| EP-3347353-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INT (DE) | 2018-05-31 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| US-9845314-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | BOEHRNGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-12-19 | — | — | US | disclosed |
| WO-2017042100-A1 | PYRAZOLYL-SUBSTITUTED HETEROARYLS AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | WO | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155751-B2 | Pyrazolyl-substituted heteroaryls and their use as medicaments | HRH4, HRH3, HRH1 | GRM2 3143/4885SIRT2 993/4885SIRT1 727/4885 |
| US-20180148433-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | GRM2 2991/4885SIRT2 906/4885SIRT1 812/4885 |
| US-20170073333-A1 | New Pyrazolyl-substituted Heteroaryls and their use as Medicaments | HRH4, HRH2, HRH3 | GRM2 2991/4885SIRT2 906/4885SIRT1 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.